Understanding how herpes simplex viruses enter human cells
Capturing HSV entry glycoprotein complexes
['FUNDING_R21'] · TUFTS UNIVERSITY BOSTON · NIH-11117997
This study is looking at how the herpes viruses get into our cells, so researchers can find new ways to create vaccines and treatments since there aren’t any good options available right now.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TUFTS UNIVERSITY BOSTON (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11117997 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which herpes simplex viruses (HSV-1 and HSV-2) enter human cells, focusing on the specific glycoprotein complexes involved in the process. The researchers aim to isolate and analyze these glycoprotein complexes using advanced techniques like cryo-electron microscopy. By understanding how these proteins interact and function, the research seeks to identify potential targets for new vaccines and therapies. This work is crucial as current treatments are not curative and there are no available vaccines.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are infected with HSV-1 or HSV-2, particularly those experiencing recurrent outbreaks or complications such as blindness.
Not a fit: Patients who are not infected with herpes simplex viruses or those who have already developed effective immunity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines and therapies for herpes simplex virus infections.
How similar studies have performed: While there has been significant research on HSV, the specific approach of isolating and analyzing glycoprotein complexes is relatively novel and has not been extensively tested.
Where this research is happening
BOSTON, UNITED STATES
- TUFTS UNIVERSITY BOSTON — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HELDWEIN, EKATERINA — TUFTS UNIVERSITY BOSTON
- Study coordinator: HELDWEIN, EKATERINA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: burden of disease